A Phase 1/2 Study of D3S-002 as Monotherapy or Combination Therapy in Adult Subjects With Advanced Solid Tumors With MAPK Pathway Mutations
Clinical trial NCT05886920 · RECRUITING
Trial details
- NCT number
- NCT05886920
- Sponsor
- D3 Bio (Wuxi) Co., Ltd
- Status
- RECRUITING
- Phase
- Phase 1, Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-07-10
- Primary completion
- 2028-08-01
- Enrollment
- 67
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.